Abstract
Upon all outcomes, premature mortality is a profound consequence of medical and psychiatric (especially depression with suicidality) comorbidities. Additionally, obesity and metabolic disturbances substantially complicate the selection and duration of trial of subsequent antipsychotic medications. This is most pronounced with respect to clozapine, wherein obesity and metabolic dysfunction now predominate and powerful influence the use of this drug as well as adjunctive therapies.
| Original language | English (US) |
|---|---|
| Title of host publication | Treatment-Refractory Schizophrenia |
| Subtitle of host publication | A Clinical Conundrum |
| Publisher | Springer Berlin Heidelberg |
| Pages | 45-64 |
| Number of pages | 20 |
| ISBN (Electronic) | 9783642452574 |
| ISBN (Print) | 9783642452567 |
| DOIs | |
| State | Published - Jan 1 2014 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
ASJC Scopus subject areas
- General Medicine
Fingerprint
Dive into the research topics of 'Medical and psychiatric comorbidities: Complicating treatment expectations'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS